Johnson Investment Counsel Inc Gilead Sciences, Inc. Transaction History

Johnson Investment Counsel Inc

$10.2 Billion
Q4 2024

A detailed history of Johnson Investment Counsel Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Johnson Investment Counsel Inc holds 16,629 shares of GILD stock, worth $1.59 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

16,629

Previous 15,080 10.27%

Holding current value

$1.59 Million

Previous $1.26 Million 21.52%

% of portfolio

0.02%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 07, 2025	BUY	$83.95 - $97.9 $130,038 - $151,647	1,549 Added 10.27%	16,629 $1.54 Million
Q3 2024 Nov 04, 2024	SELL	$66.59 - $83.99 $1.22 Million - $1.54 Million	-18,332 Reduced 54.87%	15,080 $1.26 Million
Q2 2024 Aug 08, 2024	BUY	$63.15 - $72.88 $15,219 - $17,564	241 Added 0.73%	33,412 $2.29 Million
Q1 2024 May 09, 2024	SELL	$71.58 - $87.29 $44,594 - $54,381	-623 Reduced 1.84%	33,171 $2.43 Million
Q4 2023 Feb 07, 2024	BUY	$73.27 - $83.09 $101,552 - $115,162	1,386 Added 4.28%	33,794 $2.74 Million
Q3 2023 Nov 13, 2023	SELL	$73.94 - $80.67 $84,809 - $92,528	-1,147 Reduced 3.42%	32,408 $2.43 Million
Q2 2023 Aug 10, 2023	SELL	$76.01 - $86.7 $9,273 - $10,577	-122 Reduced 0.36%	33,555 $2.59 Million
Q1 2023 May 15, 2023	BUY	$77.31 - $88.08 $216,931 - $247,152	2,806 Added 9.09%	33,677 $2.79 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $10,220 - $14,673	-164 Reduced 0.53%	30,871 $2.65 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $14,706 - $16,798	247 Added 0.8%	31,035 $1.92 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $381,875 - $430,106	6,616 Added 27.37%	30,788 $1.9 Million
Q1 2022 May 11, 2022	SELL	$57.92 - $72.58 $114,160 - $143,055	-1,971 Reduced 7.54%	24,172 $1.44 Million
Q4 2021 Feb 15, 2022	BUY	$64.88 - $73.64 $160,837 - $182,553	2,479 Added 10.48%	26,143 $1.9 Million
Q3 2021 Nov 12, 2021	SELL	$67.69 - $73.03 $41,697 - $44,986	-616 Reduced 2.54%	23,664 $1.65 Million
Q2 2021 Aug 13, 2021	SELL	$63.47 - $69.35 $15,994 - $17,476	-252 Reduced 1.03%	24,280 $1.67 Million
Q1 2021 May 14, 2021	SELL	$60.0 - $68.46 $4,680 - $5,339	-78 Reduced 0.32%	24,532 $1.59 Million
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $40,674 - $46,346	-718 Reduced 2.83%	24,610 $1.43 Million
Q3 2020 Nov 16, 2020	SELL	$62.1 - $78.08 $2,421 - $3,045	-39 Reduced 0.15%	25,328 $1.6 Million
Q2 2020 Aug 13, 2020	BUY	$72.34 - $84.0 $44,416 - $51,576	614 Added 2.48%	25,367 $1.95 Million
Q1 2020 May 20, 2020	SELL	$62.63 - $80.22 $218,265 - $279,566	-3,485 Reduced 12.34%	24,753 $1.85 Million
Q4 2019 Feb 13, 2020	SELL	$61.62 - $67.78 $55,334 - $60,866	-898 Reduced 3.08%	28,238 $1.84 Million
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $35,943 - $39,675	-575 Reduced 1.94%	29,136 $1.85 Million
Q2 2019 Aug 14, 2019	SELL	$61.87 - $69.38 $28,645 - $32,122	-463 Reduced 1.53%	29,711 $2.01 Million
Q1 2019 May 13, 2019	BUY	$62.53 - $70.05 $104,737 - $117,333	1,675 Added 5.88%	30,174 $1.96 Million
Q4 2018 Feb 13, 2019	BUY	$60.54 - $79.0 $61,266 - $79,948	1,012 Added 3.68%	28,499 $1.78 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $10,692 - $11,838	-150 Reduced 0.54%	27,487 $2.12 Million
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $59,235 - $69,095	913 Added 3.42%	27,637 $1.96 Million
Q1 2018 May 15, 2018	SELL	$72.84 - $88.8 $66,721 - $81,340	-916 Reduced 3.31%	26,724 $2.01 Million
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $51,512 - $60,468	-724 Reduced 2.55%	27,640 $1.98 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $2.05 Million - $2.42 Million	28,364	28,364 $2.3 Million

Others Institutions Holding GILD

# of Institutions

1,993

Shares Held

993M

Call Options Held

10.1M

Put Options Held

8.85M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $120B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Johnson Investment Counsel Inc, based on Form 13F filings with the SEC.

News

Stay updated on Johnson Investment Counsel Inc with notifications on news.

Account

Johnson Investment Counsel Inc Gilead Sciences, Inc. Transaction History